MANTA and MANTA-RAy Safety Readouts Boost Jyseleca’s Prospects in the US
API Manufacturers
AD/PD 2021: A New Neuro-Regenerative Therapeutic Approach Targeting Protein Kinase C for the Treatment of Alzheimer’s Disease
At the 15th International Virtual Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD) 2021, a clinical-stage biotech company based in New York, US Synaptogenix, presented its product bryostatin-1 for AD, a novel therapeutic designed to restore cognitive function and regenerate cerebral connections.
Gastrointestinal trials and hematological disorders have highest proportion of studies disrupted by Covid-19
Durvalumab’s recent failure to demonstrate improved overall survival highlights challenges in clinical development for head and neck cancer
Gilead and Galapagos discontinue IPF Phase III front-runner
Xeljanz Safety Data Could Mean Headache for JAK Inhibitor Class
Phase II Trial of Anti-Amyloid AR1001 Signals Little Promise for Patients with Alzheimer’s Disease
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
